top of page

Press


Feature Article | EIT Pharma: Interview With CEO Leen Kawas About Advancing Therapies For Hepatitis D And Viral Diseases
Pulse 2.0 sat down with Dr. Leen Kawas to talk about how EIT Pharma is built around a simple but demanding premise: find promising therapies that haven’t reached their potential, and give them the leadership and execution they need to get to patients. The interview covers her path from pharmacist to biotech CEO, the lonafarnib program for chronic hepatitis D, and what patient-centered drug development actually looks like in practice.


Feature Article | Kirkland’s EIT Pharma Announces Milestone for Drug Treating Chronic Hepatitis D
The FDA has accepted EIT Pharma's New Drug Application for lonafarnib, putting a potential first oral therapy for chronic hepatitis D into formal review. This piece covers what the milestone means for a disease with no FDA-approved oral treatments in the U.S., the D-LIVR study behind the submission, and why CEO Leen Kawas points to oral dosing and room-temperature storage as practical advantages for patients and providers.


Feature Article | Seattle-area biotech led by ex-Athira CEO Leen Kawas raises $35M for hepatitis D drug
EIT Pharma has closed an oversubscribed $35 million Series A led by Propel Bio Partners. This piece covers what the round funds — FDA review, manufacturing, and commercial prep for lonafarnib, the Kirkland company's oral candidate for chronic hepatitis D — and how the asset came to EIT through the 2024 bankruptcy sale of Eiger BioPharmaceuticals.


Feature Article | Former Athira CEO returns to Seattle biotech scene with Kirkland company
Leen Kawas is back in an operating seat. This piece covers her return to running a company as CEO of EIT Pharma after several years focused on investing through Propel Bio Partners, the venture firm she co-founded with early Athira backer Richard Kayne, and what the move means for EIT's growth in Seattle.
bottom of page